Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.7%

9 terminated/withdrawn out of 71 trials

Success Rate

80.4%

-6.1% vs industry average

Late-Stage Pipeline

3 trials in Phase 3/4

Results Transparency

1 of 37 completed trials have results

Key Signals

14 recruiting1 with results6 terminated

Enrollment Performance

Analytics

N/A

41(67.2%)

Phase 2

9(14.8%)

Phase 1

8(13.1%)

Phase 3

3(4.9%)

61Total

N/A(41)

Phase 2(9)

Phase 1(8)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (71)

Showing 20 of 71 trials

NCT02331498Phase 1Active Not Recruiting

Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

Role: lead

NCT06584747Not ApplicableActive Not Recruiting

Study of Cerebral Vascular Reserve Using Pharmacological Testing With Acetazolamide: A Non-Inferiority Study of PET Method Compared to Conventional Reference Scintigraphy

Role: lead

NCT00953537Not ApplicableCompleted

Predicting Response to Capecitabine in Women With Metastatic Breast Cancer

Role: lead

NCT00874458Not ApplicableCompleted

MRI in Assessing Tumor Size in Women With Ductal Carcinoma In Situ

Role: lead

NCT06058312Not ApplicableCompleted

Individual Food Preferences for the Mediterranean Diet in Cancer Patients

Role: lead

NCT00945451Not ApplicableCompleted

Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer

Role: lead

NCT01968304Not ApplicableCompleted

Prospective Evaluation of Iron Status in Cancer Patients Beginning Chemotherapy

Role: lead

NCT02631655Not ApplicableCompleted

POSitron Emission Imaging Using 18F-FDOPA in Neurooncology

Role: lead

NCT02104362Not ApplicableCompleted

Single Fraction Early Prostate Irradiation (SiFEPI)

Role: lead

NCT00885066Phase 1Completed

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Role: lead

NCT01977053Not ApplicableCompleted

Impact of a Telephonic Monitoring During Inter-treatment Intervals on Emotional State, Quality of Life and Toxicities, on Neo Adjuvant or Adjuvant Chemotherapy-treated Patients

Role: lead

NCT00872625Phase 1Completed

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

Role: lead

NCT02022800Not ApplicableCompleted

Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET)

Role: lead

NCT02867423Not ApplicableCompleted

Hypofractionated Radiation by CyberKnife as a Mean of the Tumor Site's Radiation After Conventional Breast Radiation.

Role: lead

NCT05664893Phase 1Withdrawn

Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)

Role: lead

NCT05931302Not ApplicableActive Not Recruiting

Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT

Role: collaborator

NCT05696288Not ApplicableCompleted

Conventional Oxygen Therapy Versus Continuous Transnasal High Flow Oxygen Therapy for Head and Neck Diagnostic Panendoscopy Under General Anesthesia in Spontaneous Ventilation

Role: lead

NCT07429487Not ApplicableNot Yet Recruiting

Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer

Role: lead

NCT07377084Recruiting

Metabolomics of Cancers of the Upper Aerodigestive Tract

Role: lead

NCT02759133Not ApplicableCompleted

Preoperative Localization of Infraclinical Breast Tumors: Isotopic Localization by iodine125 Seed Versus Standard Localization Using a Metal Wire

Role: lead